English 中文简体 中文繁体

At Alphamab Oncology, we have been discovering and developing an innovative portfolio of pipeline programs mainly driven by our proprietary technology platforms. In addition, our team has 10 years of proven in-house biologics development and manufacturing experience at Alphamab, and our strong biologics manufacturing capability with track record is another valuable asset at the company, as well as for our potential partners.

We are currently interested in partnering opportunities in the following areas:

  • (1) Partnership or out-licensing of the world-class bispecific and mix-mAb platforms at Alphamab Oncology with complementary organizations that we together can build a win-win partnership.

  • (2) Partnership with global or regional pharma/biotech companies for the development and commercialization of our clinical-stage assets in ex-China markets, to bring the next generation of cancer therapies to patients around the world.

  • (3) In-licensing or partnership for innovative oncology drugs which are synergistic to our pipeline programs.

If you have an interest in one of these areas, please direct your inquiry to bd@alphamabonc.com